Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Kesimpta (Ofatumumab) Pregnancy and Infant Safety Study Using Real World Data

NCT06156683 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT06156683
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06156683 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Kesimpta (Ofatumumab) Pregnancy and Infant Safety Study Using Real World Data
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Recruiting
Start date
June 30, 2024
Completion date
February 1, 2028
Enrollment
1,500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis